Galera Therapeutics IncOTC Pink - Current Information:GRTX
- LAST PRICE0.1368
- TODAY'S CHANGE (%)0.0018 (1.3333%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1300 / 0.1350
- Day Range
- 52 Week Range
- Volume90,646
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GRTX |
|---|---|---|
| 09:32 ET | 2600 | 0.13 |
| 09:38 ET | 2500 | 0.13 |
| 09:43 ET | 2100 | 0.135 |
| 09:48 ET | 1000 | 0.132 |
| 10:19 ET | 1100 | 0.126 |
| 10:28 ET | 350 | 0.13175 |
| 10:37 ET | 1000 | 0.126 |
| 10:42 ET | 500 | 0.1329 |
| 11:06 ET | 600 | 0.126 |
| 11:38 ET | 1550 | 0.13294 |
| 12:00 ET | 4980 | 0.1261 |
| 12:03 ET | 5000 | 0.1261 |
| 12:30 ET | 8000 | 0.1261 |
| 12:41 ET | 100 | 0.1201 |
| 12:43 ET | 25000 | 0.1261 |
| 01:24 ET | 5176 | 0.119 |
| 01:28 ET | 6259 | 0.1261 |
| 01:57 ET | 400 | 0.1261 |
| 03:48 ET | 10000 | 0.12096 |
| 03:56 ET | 2348 | 0.12 |
| 03:59 ET | 4999 | 0.1368 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galera Therapeutics Inc | 7.3M | -0.1x | --- |
NuCana PLC | 5.7M | 0.0x | --- |
NLS Pharmaceutics AG | 7.2M | -0.7x | --- |
Chromocell Therapeutics Corp | 7.6M | -0.8x | --- |
ENDRA Life Sciences Inc | 7.0M | -0.1x | --- |
National Graphite Corp | 7.7M | -2.3x | --- |
Company Information
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.
Contact Information
- Headquarters
- 45 Liberty Blvd., Suite 230MALVERN, PA, United States 19355
- Phone
- 610-725-1500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Powell
- President, Chief Executive Officer, Director
- J. Mel Sorensen
- Chief Financial Officer, Secretary
- Christopher Degnan
- Chief Legal & Compliance Officer and Secretary
- Jennifer Stacey
- Chief Medical Officer
- Eugene Kennedy
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.97 |
EPS | $-1.00 |
Book Value | $-2.41 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
